))
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists
«
»
30: From Monoclonals to Gene Therapy: Tips for Process Development w/ Neil Templeton - Part 2
Manage episode 402348255 series 3525243
内容由David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado, David Brühlmann: Biotech Entrepreneur, and Cell Culture Technology Innovation Aficionado提供。所有播客内容（包括剧集、图形和播客描述）均由 David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado, David Brühlmann: Biotech Entrepreneur, and Cell Culture Technology Innovation Aficionado 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
In our insightful second part of the conversation, we broaden our perspective to delve into the various modalities within the biotech industry, highlighting the unique and shared aspects of process development and scale-up.
Neil Templeton, the Director of Upstream Process Development at Solid Biosciences, passionately articulates his commitment towards making gene therapy more accessible. He does this by outlining strategic solutions to reduce the costs of development and manufacturing.
You will gain:
- A comprehensive understanding of process development's similarities and differences across biologics, vaccines, and cell and gene therapy manufacturing.
- Effective strategies aimed at reducing the costs associated with gene therapy development and manufacturing.
- Insights into how capitalizing on the expertise from the biologics sector can positively impact other fields.
To connect with Neil Templeton and learn more about his work, visit his LinkedIn profile.
LinkedIn: https://www.linkedin.com/in/neil-templeton
Next Step:
Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com
58集单集
分享
